Search for: "Amgen Manufacturing Limited" Results 1 - 20 of 113
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jun 2021, 4:15 am by Logan Murr
On June 21, the United States Court of Appeals for the Federal Circuit (CAFC) denied a petition for rehearing and rehearing en banc filed by Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. [read post]
8 May 2019, 12:08 pm by Lawrence B. Ebert
Sandoz prevailed against the appeal of Amgen at the CAFC:Amgen Inc. and Amgen Manufacturing Ltd. [read post]
25 Jun 2021, 4:15 am by Logan Murr
On June 21, the United States Court of Appeals for the Federal Circuit (CAFC) denied a petition for rehearing and rehearing en banc filed by Amgen Inc., Amgen Manufacturing, Limited, and Amgen USA, Inc. [read post]
26 Dec 2017, 4:15 am by Aubrey Haddach
Notably, this must be done before receiving manufacturing information from the biosimilar company. [read post]
11 Aug 2017, 6:06 am by Lawrence B. Ebert
Thus, if a sponsor forms a belief based on aninquiry limited by an applicant’s withholding of information,the sponsor has still satisfied Rule 11. [read post]
8 Jun 2023, 7:43 am by Ashwin Varma
This is the same practice that the FTC has centered on in its case against Amgen. [read post]
18 Aug 2013, 8:54 pm by Patent Docs
Teva Biopharmaceuticals USA, Inc. et al. 2:13-cv-04911; filed August 12, 2013 in the District Court of New Jersey • Plaintiffs: Amgen Inc.; Amgen Manufacturing, Limited • Defendants: Teva Biopharmaceuticals USA, Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd. [read post]
8 Jun 2023, 7:43 am by Ashwin Varma
This is the same practice that the FTC has centered on in its case against Amgen. [read post]
7 May 2009, 2:19 pm
Supreme Court agreed to consider limiting antitrust suits...Amgen IV: The Return of the Therapeutically Effective Amount In Amgen Inc., v. [read post]
27 Jan 2016, 6:52 am by Joy Waltemath
The Ninth Circuit failed to properly evaluate a class action complaint alleging breach of the duty of prudence brought by stockholders and former employees of Amgen, Inc., and its subsidiary Amgen Manufacturing, Limited, against ERISA plan fiduciaries, held the U.S. [read post]
13 Jan 2014, 2:33 pm
This leverage will no longer be available to plaintiffs seeking to punish California advertisers or importers, except in limited circumstances where a given product is manufactured exclusively in the state. [read post]
18 May 2023, 8:20 am by Dennis Crouch
In recent years, there has been a growing emphasis on promoting innovation and competition by limiting the scope of patent monopolies. [read post]
7 Jul 2020, 9:15 am by Rebecca Tapscott
District Court for the District of New Jersey in Immunex Corporation, Amgen Manufacturing, Limited, Hoffman-La Roche Inc. v. [read post]
7 Jul 2020, 9:15 am by Rebecca Tapscott
District Court for the District of New Jersey in Immunex Corporation, Amgen Manufacturing, Limited, Hoffman-La Roche Inc. v. [read post]
13 Jan 2014, 5:33 pm by Shelby Everest
This leverage will no longer be available to plaintiffs seeking to punish California advertisers or importers, except in limited circumstances where a given product is manufactured exclusively in the state. [read post]
13 Jan 2014, 5:33 pm by Shelby Everest
This leverage will no longer be available to plaintiffs seeking to punish California advertisers or importers, except in limited circumstances where a given product is manufactured exclusively in the state. [read post]
22 Dec 2022, 7:59 am by Dennis Crouch
Full Scope Enabling Written Description: The court has granted only one petition, Amgen Inc., v. [read post]